{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:04:07Z","timestamp":1792555447870,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"am","delay-in-days":286,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031230","name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011684","name":"Crohn's & Colitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK124408"],"award-info":[{"award-number":["R01DK124408"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001063","name":"Crohn's and Colitis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005615","name":"Beth Israel Deaconess Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102609","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:57:33Z","timestamp":1752598653000},"page":"102609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Can we cure autoimmune hepatitis?"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4510-1249","authenticated-orcid":false,"given":"Maria Serena","family":"Longhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Mieli-Vergani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Vergani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102609_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2007.08.013","article-title":"Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis","volume":"48","author":"Al-Chalabi","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102609_bib2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_bib3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1365-2249.2000.01280.x","article-title":"Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis","volume":"121","author":"Costa","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(87)92024-1","article-title":"Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen","volume":"1","author":"Manns","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102609_bib5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","article-title":"Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease","volume":"35","author":"Ma","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_bib6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI113949","article-title":"Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1","volume":"83","author":"Manns","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102609_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/0891693021000054101","article-title":"Frequency and significance of antibodies to soluble liver antigen\/liver pancreas in variant autoimmune hepatitis","volume":"35","author":"Czaja","year":"2002","journal-title":"Autoimmunity"},{"key":"10.1016\/j.coi.2025.102609_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0016-5085(99)70186-1","article-title":"Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis","volume":"116","author":"Lapierre","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102609_bib9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_bib10","first-page":"113","article-title":"[Liver, blood proteins and nutritive protein]","volume":"9","author":"Waldenstrom","year":"1953","journal-title":"Dtsch Z Verdau Stoffwechs"},{"key":"10.1016\/j.coi.2025.102609_bib11","first-page":"1323","article-title":"Lupoid hepatitis","volume":"271","author":"Cowling","year":"1956","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102609_bib12","article-title":"Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression","volume":"6","author":"Zhao","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102609_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_bib14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","author":"European Association for the Study of the","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102609_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","article-title":"Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis","volume":"42","author":"Luth","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.coi.2025.102609_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pedia Gastroenterol Nutr"},{"key":"10.1016\/j.coi.2025.102609_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102609_bib18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102609_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/cei.12956","article-title":"Immunosuppressive drugs affect interferon (IFN)-gamma and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis","volume":"189","author":"Grant","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/apt.15528","article-title":"Adverse events related to low dose corticosteroids in autoimmune hepatitis","volume":"50","author":"van den Brand","year":"2019","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.coi.2025.102609_bib21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cgh.2016.12.040","article-title":"Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis","volume":"16","author":"Peiseler","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102609_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.mpg.0000232331.93052.dd","article-title":"Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis","volume":"43","author":"Banerjee","year":"2006","journal-title":"J Pedia Gastroenterol Nutr"},{"key":"10.1016\/j.coi.2025.102609_bib23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/MEG.0b013e32832ad5f7","article-title":"Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis: a single centre experience on 55 children","volume":"21","author":"Dumortier","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102609_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaci.2022.09.010","article-title":"Azathioprine therapy induces selective NK cell depletion and IFN-gamma deficiency predisposing to herpesvirus reactivation","volume":"151","author":"Ingelfinger","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","volume":"14","author":"Hubener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102609_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2014.02.001","article-title":"Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2","volume":"53","author":"Holder","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102609_sbref27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183776","article-title":"Clonal analysis of SepSecS-specific B and T cells in autoimmune hepatitis","volume":"135","author":"Kramer","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102609_bib28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the International Autoimmune Hepatitis Group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.coi.2025.102609_bib29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.humimm.2007.03.010","article-title":"Elevated serum BAFF levels in patients with autoimmune hepatitis","volume":"68","author":"Migita","year":"2007","journal-title":"Hum Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003194","article-title":"B-cell activating factor belonging to the tumor necrosis factor family and interferon-gamma-inducible protein-10 in autoimmune hepatitis","volume":"95","author":"Nishikawa","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.coi.2025.102609_bib31","article-title":"Standard immunosuppressive treatment reduces regulatory B cells in children with autoimmune liver disease","volume":"13","author":"Yuksel","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","article-title":"Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease","volume":"3","author":"Atreya","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2025.102609_bib33","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","article-title":"Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies","volume":"61","author":"Taubert","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102609_sbref34","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.immuni.2024.08.005","article-title":"Autoantigen-specific CD4(+) T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases","volume":"57","author":"Saggau","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102609_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.27884","article-title":"In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression","volume":"62","author":"Liberal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_bib36","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","article-title":"Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis","volume":"176","author":"Longhi","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.22071","article-title":"Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis","volume":"47","author":"Longhi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_bib38","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2012.02.041","article-title":"Inhibition of interleukin-17 promotes differentiation of CD25(-) cells into stable T regulatory cells in patients with autoimmune hepatitis","volume":"142","author":"Longhi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coi.2025.102609_bib39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hep.24039","article-title":"Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis","volume":"53","author":"Longhi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_bib40","doi-asserted-by":"crossref","first-page":"E3432","DOI":"10.1073\/pnas.1408780111","article-title":"Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions","volume":"111","author":"Lu","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2025.102609_bib41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhepr.2019.08.001","article-title":"Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis","volume":"1","author":"Oo","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.coi.2025.102609_sbref42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103172","article-title":"The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial","volume":"144","author":"Lorenzon","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102609_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102609_bib44","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.30059","article-title":"Low-dose interleukin-2 for refractory autoimmune hepatitis","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_sbref45","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","article-title":"Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics","volume":"57","author":"Raeber","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102609_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb9283","article-title":"Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species","volume":"12","author":"Karakus","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102609_bib47","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2025.102609_bib48","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20040180","article-title":"CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes","volume":"199","author":"Tarbell","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2025.102609_bib49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/eji.200839073","article-title":"Curing CNS\u00a0autoimmune disease with myelin-reactive Foxp3+ Treg","volume":"39","author":"Stephens","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib50","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI17702","article-title":"Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia","volume":"112","author":"Trenado","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102609_bib51","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.2174\/138161211798157568","article-title":"Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis","volume":"17","author":"Czaja","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.coi.2025.102609_bib52","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0952-7915(00)00166-7","article-title":"Antigen-specific therapy for autoimmune disease","volume":"12","author":"Harrison","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2025.102609_sbref54","article-title":"Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102609_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1463971","article-title":"Regulatory CD4(+) T cells redirected against pathogenic CD8(+) T cells protect NOD mice from development of autoimmune diabetes","volume":"15","author":"Kakabadse","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102609_sbref56","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn3470","article-title":"Effector memory-type regulatory T cells display phenotypic and functional instability","volume":"10","author":"Wendering","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.coi.2025.102609_bib57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm1564","article-title":"Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation","volume":"13","author":"Korn","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2025.102609_bib58","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hep.25682","article-title":"The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway","volume":"56","author":"Liberal","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.coi.2025.102609_bib59","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1038\/s41423-021-00790-w","article-title":"Activation of AMPKalpha1 is essential for regulatory T cell function and autoimmune liver disease prevention","volume":"18","author":"Zhu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2025.102609_bib60","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2023.05.020","article-title":"Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics","volume":"79","author":"Uzun","year":"2023","journal-title":"J Hepatol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:21:19Z","timestamp":1757337679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":60,"alternative-id":["S0952791525000858"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102609","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we cure autoimmune hepatitis?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102609"}}